JPRN-UMIN000018721已完成未知
Pharmacokinetic, pharmacodynamic and biomarker study of phase I/II study of olaparib in combination with eribulin mesylate for patients with recurrent or metastatic triple-negative-type breast cancer - Pharmacokinetic, pharmacodynamic and biomarker study of Eribulin and Olaparib study
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patient considered irrelevant by attending physician for the study
研究者
相似试验
进行中（未招募）
1 期
Pharmacokinetics and Pharmacodynamic Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis (PROPHETIC Study)EUCTR2019-003780-21-NLAlimentiv Inc.40
已完成
不适用
Pharmacokinetics and Pharmacodynamic Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis (PROPHETIC Study)Ulcerative colitisNL-OMON54935Alimentiv B.V.13
进行中（未招募）
1 期
Metabolism and effects of naloxone given as a spray in healthy volunteers and children.Sedation after opioid administrationPharmacokinetic profile after naloxone administered intranasallyEUCTR2013-005201-31-SEKarolinska University Hospital20
尚未招募
不适用
A study on the pharmacokinetics and pharmacodynamics of remimazolam during total intravenous anesthesia with remifentanilKCT0007066Inje University Busan Paik Hospital15
招募中
不适用
Pharmacokinetic, pharmacodynamic and pharmacogenetic research on biomarkers in cancer patients with special response to pharmacological therapyMalignancyJPRN-UMIN000011798Medical Oncology / Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine600